Revive Therapeutics has begun the development of a next-generation formulation of Bucillamine to treat public health emergencies.
Such emergencies include infectious disease outbreaks, pandemic influenza and medical incidents or attacks requiring countermeasures.
Revive will also assess the use of the new Bucillamine formulation as a potent antioxidant and anti-inflammatory therapy for orphan indications in rare inflammatory disorders.
These disorders may consist of ischemia-reperfusion injury, which arises from solid organ transplantation.
The Canada-based company has signed a sponsored research agreement with the University of Waterloo, Canada, to develop a new lyophilised injectable formulation of Bucillamine for rare inflammatory disorders and medical emergencies.
The Wettig Research Group will carry out the research initiative under the guidance of the principal investigator and the University of Waterloo Graduate Studies assistant vice-president Professor Shawn Wettig.
Wettig’s research focuses on areas such as solution thermodynamics, cell biology, biochemistry and physical chemistry, all of which are applied to assess self-assembling systems.
The design of new surface-active compounds is a crucial aspect of Wettig’s research. These compounds offer improved pharmaceutical applications such as targeted delivery and enhanced bio-distribution of an active compound.
They also offer the necessary self-assembly characteristics and control of particle dimensions on a nanometer-size scale.
The formulation’s development is expected to be completed by the end of this year.
The company then plans to begin research studies to progress the clinical and commercial growth of Bucillamine.
Source link
#Revive #begins #development #nextgeneration #Bucillamine
